SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 16, 2000
IMMUNOMEDICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-12104 61-1009366
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
300 American Road, Morris Plains, New Jersey 07950
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (973) 605-8200
(Former name or former address, if changed since last report)
Item 5. Other Events
On February 16, 2000, the registrant completed a private placement of
2.325 million shares of its Common Stock for a total purchase price of $37.2
million. The shares were not registered under the Securities Act of 1933 and may
not be offered or sold in the United States absent registration or an applicable
exemption from registration requirements. The registrant is obligated to file a
registration statement with the Securities and Exchange Commission covering the
resale of such shares.
Item 7. Financial Statements and Exhibits
Exhibit 99.1 Press Release dated February 17, 2000
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
IMMUNOMEDICS, INC.
By: /s/ David M. Goldenberg
---------------------------
David M. Goldenberg,
Chairman of the Board and
Chief Executive Officer
Date: February 23, 2000
-3-
EXHIBIT INDEX
Exhibit 99.1 Press Release dated February 17, 2000
-4-